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ABSTRACT
Background. Early detection of acute kidney injury (AKI) is
important for safe clinical practice. NHS England is imple-
menting a nationwide automated AKI detection system based
on changes in blood creatinine. Little has been reported on
the similarities and differences of AKI patients detected by
this algorithm and other deﬁnitions of AKI in the literature.
Methods. We assessed the NHS England AKI algorithm and
other deﬁnitions using routine biochemistry in our own health
authority in Scotland in 2003 (adult population 438 332).
Linked hospital episode codes (ICD-10) were used to identify
patients where AKI was a major clinical diagnosis. We com-
pared how well the algorithm detected this subset of AKI pa-
tients in comparison to other deﬁnitions of AKI. We also
evaluated the potential ‘alert burden’ from using the NHS Eng-
land algorithm in comparison to other AKI deﬁnitions.
Results.Of 127 851 patients with at least one blood test in 2003,
the NHS England AKI algorithm identiﬁed 5565 patients. The
combined NHS England algorithm criteria detected 91.2%
(87.6–94.0) of patients who had an ICD-10 AKI code and
this was better than any individual AKI deﬁnition. Some of
those not captured could be identiﬁed by algorithm modiﬁca-
tions to identify AKI in retrospect after recovery, but this would
not be practical in real-time. Any modiﬁcations also increased
the number of alerted patients (2-fold in the most sensitive
model).
Conclusions. The NHS England AKI algorithm performs well
as a diagnostic adjunct in clinical practice. In those without
baseline data, AKI may only be seen in biochemistry in retro-
spect, therefore proactive clinical care remains essential. An
alternative algorithm could increase the diagnostic sensitivity,
but this would also produce a much greater burden of patient
alerts.
Keywords: acute kidney injury, diagnosis, epidemiology,
screening
INTRODUCTION
Acute kidney injury (AKI) is a serious condition complicating
one in seven hospital admissions [1]. It is usually diagnosed
from rapidly deteriorating blood tests (serum creatinine) or
urine output. It can occur in any clinical setting, leading to sub-
stantially increased hospital mortality (one in three in severe
AKI) [2], morbidity and healthcare costs (£1billion/year in
NHS England) [1, 2].
AKI must be recognized early with appropriate intervention
or monitoring. In the UK, a National Conﬁdential Enquiry into
Patient Outcome andDeath (NCEPOD) found suboptimal care
in 50% of patient deaths from AKI, with delays in care and
preventable harm [3]. A simple system is therefore needed to
improve early detection in AKI across healthcare settings [4].
In response, NHS England plans amandatory national auto-
mated algorithm for detecting AKI [5]. The algorithm is based
on the Kidney Disease: Improving Global Outcomes (KDIGO)
AKI deﬁnition [6]. Changes in serum creatinine are tracked in a
biochemistry system with each new (index) test compared with
previous (reference) results. An AKI ‘alert’ can be generated if
sufﬁcient change in creatinine has occurred in a short space of
time. One of three criteria should be satisﬁed, differing in the
time period of creatinine change (Table 1). AKI stage can also
be calculated, based on the magnitude of creatinine rise [6].© The Author 2015. Published by Oxford University Press
on behalf of ERA-EDTA. This is an Open Access article distributed under the
terms of theCreativeCommonsAttribution License (http://creativecommons.org/
licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction
in any medium, provided the original work is properly cited.
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This algorithm may help clinicians recognize AKI early, and
may be of use in audit and clinical research [5].
The NHS England AKI algorithm is novel, but an awareness
of its strengths, weaknesses and any unintended consequences
is essential. Previous automated AKI detection systems have
been reported, but not on a national scale [7–12], and while
their successful implementation is encouraging, there are calls
for them to prove their diagnostic value [13]. In particular, it is
necessary to recognize the acute changes of AKI from chronic
kidney disease (CKD)—a challenge in routine healthcare when
not all patients have recent tests for comparison [14]. The NHS
England algorithm also differs from previous approaches for
identifying AKI. Previous algorithms have varied in deﬁnitions
and been of lower complexity using only a single reference cri-
terion rather than a combination [7–11]. Some have also in-
volved a human step in determining reference creatinine [7,
9]. In clinical research, a longer look-back period [14, 15], im-
putation of missing results [16, 17] or a subsequent fall in cre-
atinine during follow-up have all been suggested when previous
results are unavailable [2, 18, 19].
Once the algorithm identiﬁes possible AKI, it is up to the
clinician to interpret. Consequently, to maximize clinical bene-
ﬁt from an AKI algorithm, clinicians must understand which
patients may be incorrectly identiﬁed (false positives), whether
AKI patients may be missed (false negatives), and how to act
when warned by an alert. Similarly, to study AKI prognosis it
is important to ﬁrst understand how different AKI deﬁnitions
could cause selection biases in clinical research. An alternative
standard is needed to compare these deﬁnitions.
Clinically coded AKI provides an alternative mechanism to
identify a subset of AKI that has been conﬁrmed clinically by
the treating physicians and subsequently coded. World Health
Organisation International Classiﬁcation of Disease (ICD-10)
codes for diagnosis are routinely collected on hospital discharge
in the UK and are used for healthcare planning [20]. ICD-10
codes are highly speciﬁc for AKI, but only report a subset of all
AKI [21]. The high speciﬁcity of ICD-10 AKI has been shown in
US administrative coding (for billing) [22] and similar high spe-
ciﬁcity (95%) was observed in a single-centre UK study using
ICD-10 codes in 2005 and 2010 [23]. Thus, while not all AKI
patients are coded, ICD-10 AKI patients have a reliable diagnosis
and should not be missed by a sensitive screening algorithm.
The Grampian Laboratory Outcomes, Morbidity and
Mortality Study-II (GLOMMS-II) cohort is a population
based cohort from 1 of 14 health authorities in NHS Scotland
with an adult population of 438 332 [24]. It includes all patients
from the index year (2003) with renal impairment (estimated
glomerular ﬁltration rate, eGFR < 60 mL/min/1.73m2) and a
sample of patients with normal kidney function (eGFR ≥ 60
mL/min/1.73m2) (Figure 1). GLOMMS-II is an established
platform for observing the prognosis of kidney diseases and
contributes to the international CKD Prognosis Consortium
[25]. This large regional cohort has been linked to ICD-10
data and provides an opportunity to rapidly contrast the impli-
cations of different biochemical deﬁnitions of AKI [26]. While
cohort inception was 2003 and coding of AKI has since in-
creased, the speciﬁcity of ICD-10 AKI codes has remained
high through this period [23].
The NHS England algorithm ismandatory in England and is
based on sound principles, but as yet is not validated. Therefore,
we report here how their algorithm performs in our own health
authority in NHS Scotland. We used GLOMMS-II to compare
the NHS AKI algorithm and other recognized biochemistry
deﬁnitions with coded ICD-10 AKI episodes. We studied
how many patient-alerts these deﬁnitions involved and what
proportion of ICD-10 AKI coded patients were detected
(sensitivity).
MATERIALS AND METHODS
Study population—the GLOMMS-II cohort
Grampian is a region of north-east Scotland served by a sin-
gle biochemistry service, which provided the biochemistry in
GLOMMS-II. The service processes blood samples regardless
of clinical setting, whether hospital, community or private
(i.e. outside NHS). All serum creatinines were isotope dilution
mass spectrometry aligned. The estimated mid-year resident
adult (≥15 years) population of Grampian was 438 332 in
2003, of which 127 851 (29.2%) had at least one serum creatin-
ine test. For linkage, we included all adults with an abnormal
kidney blood test (eGFR < 60 mL/min/1.73m2) in 2003 (n = 29
729) and a 20% sample of those with normal tests (n = 19 989)
as subgroups for study (Figure 1).
Data linkage
We linked GLOMMS-II to the Scottish Renal Registry and
local renal management system to exclude patients receiving
chronic renal replacement therapy (RRT). We also linked
GLOMMS-II to nationally collected hospital episode data in-
cluding hospital diagnoses for each admission over 10 years
(1999–2009) using ICD-10. Data linkage involved deterministic
matching using the Community Health Index, a unique identi-
ﬁer for all residents in Scotland. In this study, 94.9% of patients
could be linked to at least one hospital admission for retrieval of
ICD-10 codes. We obtained approval from the appropriate
Privacy Advisory and ethics panels. The data were hosted and
managed by Grampian Data Safe Haven [27].
Table 1. NHS automated AKI algorithm
AKI criteria Deﬁnition for AKI (one of the three)
Criterion 1 Serum creatinine≥1.5 times higher than themedian of all
creatinines 8–365 days ago
Criterion 2 Serum creatinine ≥1.5 times higher than the lowest
creatinine within 7 days
Criterion 3 Serum creatinine >26 μmol/L higher than the lowest
creatinine within 48 h
AKI Stage Classiﬁcation requirements
Stage 1 Rise in creatinine of >26 or index/reference ≥1.5 and <2
Stage 2 Index/reference ≥2 and <3
Stage 3 Index/reference ≥3 or ≥1.5 and index creatinine >354
μmol/L (or three times the upper reference interval if
age <18)
AKI can be diagnosed if one of three criteria is met. Staging is based on a comparison of a
serum creatinine (index) with a reference test. Where a creatinine is outside the reference
range but a previous creatinine within 1 year is unavailable, the test is ‘ﬂagged’ abnormal
(with chronicity uncertain).
O
R
IG
IN
A
L
A
R
T
IC
L
E
1854 S. Sawhney et al.
 at U
niversity of A
berdeen on O
ctober 28, 2015
http://ndt.oxfordjournals.org/
D
ow
nloaded from
 
Population characteristics
We collectedmorbidity data for ischaemic heart disease, car-
diac failure, diabetes mellitus and previous renal disease from
ICD-10 codes using a previously described look-back period
of 5 years (1 January 1998–31 December 2002) [28]. We also
collected data on patient location at AKI diagnosis, frequency
of blood testing and baseline renal impairment. We used the
four-variable Modiﬁcation of Diet in Renal Disease (MDRD)
eGFR equation to describe baseline renal impairment.
Reference standard—ICD-10 AKI
We extracted all ICD-10 codes for acute renal failure (N17)
in any diagnostic position (maximum six available) on dis-
charge between 1 January 2003 and 31 December 2003. We
F IGURE 1 : Summary of the GLOMMS-II Study Population. eGFR, estimated glomerular ﬁltration rate; RRT, renal replacement therapy.
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labelled patients as ICD-10 AKI positive or negative based on
whether they had at least one ICD-10 AKI episode in 2003.
Biochemical AKI algorithm
For each patient, we identiﬁed the ﬁrst episode of biochem-
ical AKI in 2003. We used the NHS England AKI algorithm, re-
quiring at least one of criteria 1–3 in Table 2. For instance,
criterion 1 requires an index creatinine ≥1.5-fold higher than
the median creatinine of the previous 8–365 days. Three
other criteria, 4–6, based on methods used in previous studies
were also assessed [2, 8, 9, 11, 18, 19]. We deviated from the al-
gorithm in two respects. As sample time data were incomplete,
we calculated creatinine changes using days rather than hours.
Where blood tests were repeated on the same day, we included
the highest creatinine. In both cases, we checked the impact on
sensitivity analyses.
Biochemical AKI stage
We calculated AKI stage based on creatinine rises in NHS
England algorithm criteria (Table 1). We reported the highest
stage within 30 days of ﬁrst detection. If more than one refer-
ence creatinine was available the value providing the highest
AKI stage was used. We also reported the stage at ﬁrst AKI de-
tection to assess progression to AKI Stage 3 from lower AKI
stages.
Analysis
We summarized patient characteristics at baseline including
morbidities, number with biochemical AKI and ICD-10 AKI.
We stratiﬁed by the biochemical AKI stage, comparing co-
morbidities, ICD-10 AKI, number of alerts and patient location
at ﬁrst AKI detection. We also compared the characteristics of
ICD-10 AKI patients detected and missed by the algorithm.
For biochemical AKI, we reported ‘sensitivity’ using ICD-10
AKI as the reference standard. We did this ﬁrst for each bio-
chemical criterion, then for the NHS England AKI algorithm
(criteria 1–3, model A) and ﬁnally we compared these with
alternative deﬁnitions of AKI by incrementally adding criteria
4–6 to themodel (models B, C andD).We calculated sensitivity
by dividing the number of patients with biochemical and
ICD-10 AKI by number of patients with ICD-10 AKI, with
95% conﬁdence intervals. As ICD-10 includes only a subset
of AKI, we did not feel it would be appropriate to report positive
predictive values, speciﬁcity or a receiver operating characteris-
tic curve.
To estimate the Grampian incidence of AKI based on NHS
England algorithm criteria, we used the entire Grampian bio-
chemistry dataset (n = 127,851) rather than those in the linked
cohort (n = 49,718) and reported the number that met the AKI
algorithm criteria in 2003. All analysis was conducted using
Stata/SE 13.0 (StataCorp 2013).
RESULTS
Patient characteristics
For a cohort of 49 718 patients, there were 215 461 blood
tests in 2003, 128 741 during hospital admissions and 86 720
from outpatients and the community. There were 4545 patients
with 14 127 biochemical AKI alerts. Table 3 summarizes the
characteristics of patients with abnormal and normal kidney
function. In the abnormal eGFR group, biochemical AKI by
NHS England criteria was present in 4373 (14.7%) patients
and ICD-10 AKI in 329 (1.1%) patients. In the normal eGFR
group, biochemical AKI was present in 172 (0.9%) patients
and ICD-10 AKI in <5 patients. Patients with an abnormal
eGFR were older and had more ischaemic heart disease, cardiac
failure, diabetes or previous renal disease than patients with a
normal eGFR (Table 3). The majority of index creatinine tests
could be compared with a previous reference test within 1 year
(92.1% abnormal eGFR group, 68.5% normal eGFR group). In
2003, the median number of tests per patient was two.
Description of biochemical AKI using the NHS
England algorithm
As few (<5) had ICD-10 AKI (reference standard) in the
normal eGFR group, we report here only patients with and
without biochemical AKI and ICD-10 AKI in the abnormal
eGFR group (Table 4, Figure 2).
ICD-10 AKI was present in more patients with biochemical
AKI than without biochemical AKI (6.9 versus 0.1%). The ma-
jority were in hospital at ﬁrst detection (80.7%) although only
45.9% had had a blood test in the previous 2 days. Patients with
biochemical AKI had more previous ischaemic heart disease,
cardiac failure, diabetes mellitus and renal disease than those
without biochemical AKI.
The peak AKI stage was Stage 1 for 2957, Stage 2 for 865 and
Stage 3 for 551 patients. The median number of alerts increased
over AKI Stages 1–3 (1, 3 and 5 alerts, respectively); as did the
proportion of patients with ICD-10 AKI (2.5, 8.2 and 27.9%,
respectively) (Figure 3). Of those with peak AKI of Stage 3,
264 (47.9%) had progressed from Stages 1 and 2 at initial
detection.
Twenty-nine (8.8%) patients with ICD-10 AKI were missed
by NHS England AKI criteria (Table 5). ICD-10 AKI patients
Table 2. AKI criteria based on the relationship between a blood test
of interest and a reference creatinine
NHS
algorithm
AKI criteria Time
period
Reference creatinine Relationship
Y Criterion 1 8–365
days
Median of all
creatinines previous
8–365 days
Ratio≥ 1.5
Y Criterion 2 1–7 days Lowest creatinine in
previous 7 days
Ratio≥ 1.5
Y Criterion 3 48 hours Lowest creatinine in
previous 48 h
Rise > 26
μmol/L
N Criterion 4 30 days
(future)
Lowest creatinine
within 30 days after
index
Ratio≥ 1.5
N Criterion 5 3 years Most recent
creatinine in
previous 3 years
Ratio≥ 1.5
N Criterion 6 8–365
days
Lowest creatinine in
previous 8–365 days
Ratio≥ 1.5
The NHS AKI algorithm required one of criteria 1–3 (denoted ‘Y’) to be met. Criteria 4–6
are alternative criteria used in previously in clinical research.
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Table 4. The NHS AKI algorithm by peak AKI stage in patients with eGFR < 60 mL/min/1.73m2
Peak NHS AKI algorithm alert AKI Stage 1 AKI Stage 2 AKI Stage 3 Any AKI No AKI
N 2957 865 551 4373 25 356
Male sex (%) 1320 (44.6) 401 (46.4) 286 (51.9) 2007 (45.9) 8987 (35.4)
Age (IQR) 76 (67–83) 76 (65–83) 73 (62–81) 76 (66–83) 74 (66–81)
Age≥ 70 (%) 2059 (69.6) 576 (66.6) 328 (59.5) 2963 (67.8) 16 627 (65.6)
IHD (%) 701 (23.7) 176 (20.3) 110 (20.0) 987 (22.6) 3525 (13.9)
CCF (%) 372 (12.6) 86 (10.0) 68 (12.3) 526 (12.0) 1342 (5.3)
Diabetes (%) 391 (13.2) 91 (10.5) 71 (12.9) 553 (12.7) 1568 (6.2)
Renal disease (%) 273 (9.2) 67 (7.7) 77 (14.0) 417 (9.5) 1224 (4.7)
ICD-10 AKI (%) 75 (2.5) 71 (8.2) 154 (27.9) 300 (6.9) 29 (0.1)
Reference eGFR (IQR) 65.4 (48.5–82.8)) 71.4 (53.6–93.6) 70.6 (45.9–95.4) 67.0 (49.2–85.7) –
Reference eGFR < 30 (%) 203 (6.9) 19 (2.2) 81 (14.7) 303 (6.9) –
Alerts received (IQR) 1 (1–2) 3 (2–5) 5 (3–9) 2 (1–4) –
Community at ﬁrst AKI alert (%) 636 (21.5) 130 (15.0) 78 (14.2) 844 (19.3) –
Inpatient at ﬁrst AKI alert (%) 2321 (78.5) 735 (85.0) 473 (85.8) 3529 (80.7) –
First alert >2 days after last test (%) 1511 (51.1) 517 (59.8) 339 (61.5) 2367 (54.1) –
First alert within 2 days of last test (%) 1446 (48.9) 348 (40.2) 212 (38.5) 2006 (45.9) –
First alert more than 7 days after last test (%) 1132 (38.3) 394 (45.5) 268 (48.6) 1794 (41.0) –
First alert within 7 days of last test (%) 1825 (61.7) 471 (54.5) 283 (51.4) 2579 (59.0) –
Summary data as median and interquartile range (IQR) where appropriate.
eGFR, estimated glomerular ﬁltration rate; IHD, ischaemic heart disease; CCF, congestive cardiac failure; AKI, acute kidney injury.
Table 3. Characteristics of the GLOMMS-II Cohort
Group Abnormal eGFR in 2003 Normal eGFR in 2003 (20% sample) Overall
N 29 729 19 989 49 718
Male sex (%) 10 994 (37.0) 9460 (47.3) 20 454 (41.1)
Age (IQR) 74 (66–81) 53 (39–66) 68 (54–78)
Age≥ 70 (%) 19 590 (65.9) 3580 (17.9) 23 170 (46.6)
IHD (%) 4512 (15.2) 1019 (5.1) 5531 (11.1)
CCF (%) 1868 (6.3) 175 (0.9) 2043 (4.1)
Diabetes (%) 2121 (7.1) 397 (2.0) 2518 (5.1)
Renal disease (%) 1641 (5.5) 299 (1.5) 1940 (3.9)
ICD-10 AKI (%) 329 (1.1) <5 (–)a <334 (0.7)a
Biochemical AKI (%) 4373 (14.7) 172 (0.9) 4545 (9.5)
Criterion 1 (8–365 days) (%) 3277 (11.0%) 80 (0.4%) 3357 (6.8%)
Criterion 2 (1–7 days) (%) 1895 (6.4%) 101 (0.5%) 1996 (4.0%)
Criterion 3 (48 h) (%) 2218 (7.4%) 36 (0.2%) 2254 (4.5%)
Highest eGFR in 2003 (IQR) 57.2 (49.0–67.2) 84.6 (74.4–97.9) 70.0 (55.0–85.3)
Median no. of tests (IQR) 2 (1–6) 1 (1–2) 2 (1–4)
Reference test < 1 year (%) 152 308 (92.1) 29 550 (68.5) 181 858 (87.2)
Summary data as median and interquartile range (IQR) where appropriate; eGFR, estimated glomerular ﬁltration rate; IHD, ischaemic heart disease; CCF, congestive cardiac failure.
aSuppressed information to prevent patient identiﬁcation.
F IGURE 2 : Sensitivity for ICD-10AKI. Firstly of each of the individual AKI criteria (1–6) and then the combined criteria of theNHSAKI algorithm
(model A) and modiﬁed algorithms (models B, C and D). Sensitivity with 95% conﬁdence limits. B, Biochemical AKI; C, ICD-10 AKI. Note that
combining criteria 2 and 3 detects 2748 patients with biochemical AKI, 244 with ICD-10 AKI and 85 without (sensitivity 74.2%, 69.1–78.8).
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missed were of similar age, sex and peak eGFR to those not
missed, but had less ischaemic heart disease (13.8 versus
24.3%), cardiac failure (10.3 versus 15.3%) and diabetes (3.4
versus 15.7%) (Table 5).
Biochemical AKI deﬁnitions versus ICD-10 AKI
Six different criteria (Table 2) for the reference value used to
deﬁne biochemical AKI are evaluated in Figure 2. The number
with AKI identiﬁed by each criterion ranged from 1895 to 5512.
The proportion of ICD-10 AKI patients identiﬁed by each cri-
terion (sensitivity) ranged from 55.9% (lowest creatinine 1–7
days) to 87.2% (lowest creatinine 8–365 days) (Figure 2).
NHS England AKI criteria, model A, deﬁnes AKI if one of
criteria 1–3 is met (Table 2); 4373 patients had biochemical
AKI by NHS England criteria and this included 300 of 329 pa-
tients with ICD-10 AKI (91.2% sensitivity). The algorithm
missed 29 ICD-10 AKI patients (8.8%). The incremental add-
ition of further criteria (models B, C and D) improved algo-
rithm sensitivity. Adding a retrospective diagnosis (model B)
reduced the number of patients missed to 16 (95.1% sensitive)
and combining all criteria (model D) reduced this to 11 (96.7%
sensitive), but with 7106 patients alerted (2733 more than
model A).
Population incidence of ﬁrst episode of AKI
Wealso usedNHSEngland algorithm criteria to estimate the
incidence of AKI in unlinked biochemistry data for the entire
adult Grampian population in the region in the same year
(2003). There were 5565 patients with AKI out of an adult
population of 438 332, of which 127 851 had blood tests. This
equates to 12 696 adult patients per million population per year.
In comparison, twice as many patients (10 811 patients, 24 664
per million population/year) met AKI model D criteria.
DISCUSSION
In a large Scottish cohort, we assessed the sensitivity of the NHS
England AKI biochemistry algorithm for an ICD-10 clinically
conﬁrmed subset of AKI patients. Using NHS England criteria,
the 1-year risk of at least one AKI episode was estimated at
12 696 per million population and appropriately, ICD-10 AKI
patients made up a greater proportion of patients with Stage 3
AKI (27.9%) than Stage 1 AKI (2.5%).
Encouragingly, NHS England algorithm criteria detected
91.2% of ICD-10 AKI. The 29 (8.8%) patients missed had simi-
lar age and kidney function (by peak eGFR) to those detected,
but a lower proportion of diabetes and cardiac disease. Less fre-
quent follow up in these patients may have resulted in fewer
blood tests from which to diagnose AKI. The combination of
criteria in the NHS England algorithm missed fewer ICD-10
AKI patients than any individual criterion.
Adding a retrospective diagnosis of AKI if serum creatinine
subsequently fell captured half of the cases missed byNHS Eng-
land criteria although this strategy would not be possible in
real-time clinical practice. Further improvements in sensitivity
could also be achieved by lengthening the look-back period or
adding lowest rather than median creatinine criteria. An 8–
365-day median criterion may have under-detected a minority
F IGURE 3 : Number of patients at each stage by the NHS AKI algorithm and number with ICD-10 AKI. (Scaled representation). Includes
29 patients missed by the algorithm.
Table 5. ICD-10 AKI patients detected and missed by the NHS AKI
algorithm.
Patients with ICD-10 AKI Detected by AKI
algorithm
Missed by AKI
algorithm
N (%) 300 (91.2) 29 (8.8)
Male (%) 155 (51.7) 15 (51.7)
Age (IQR) 75 (65–82) 77 (59–85)
Age≥ 70 (%) 199 (66.3) 18 (62.1)
IHD (%) 73 (24.3) 4 (13.8)
CCF (%) 46 (15.3) 3 (10.3)
Diabetes (%) 47 (15.7) 1 (3.4)
Renal disease (%) 53 (17.7) 7 (24.1)
Highest eGFR in 2003 (IQR) 60.4 (39.9–87.2) 59.1 (34.8–77.0)
Summary data as median and interquartile range (IQR) where appropriate.
eGFR, estimated glomerular ﬁltration rate; IHD, ischaemic heart disease; CCF, congestive
cardiac failure; AKI, acute kidney injury.O
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of patients by providing a falsely high reference creatinine in
some patients. Thus, using algorithm model D, only 11 cases
were missed (3.3%). Each modiﬁcation, however, resulted in
substantially more patients alerted, up to 2-fold when the
most sensitive model (D) was tested in the full Grampian popu-
lation. This implies the presence of false positives.
Our assessment of the NHS England AKI algorithm has
strengths in size and completeness covering an entire regional
population, with availability of outpatient and private blood
tests enabling us to use the AKI algorithm without the need
for a hospital admission. A detailed comparison with other de-
ﬁnitions also highlights the strengths of the algorithm. In the
abnormal eGFR group, 92.1% of tests had a reference test within
1 year and 97.3% of these patients were linkable to an ICD-10
proﬁle. The remaining 2.7% represent people without any re-
cord of hospital admissions (1999–2009). Exclusion of patients
receiving chronic RRT prevented misclassiﬁcation.
A difﬁculty among AKI studies is the absence of a perfect
gold standard for assessing diagnostic accuracy. In previous at-
tempts to deﬁne baseline kidney function, Siew et al. [15] tested
a selection of baseline deﬁnitions using as reference standard an
adjudicated value determined by two nephrologists. In their
study of CKD and AKI patients with at least two previous
tests within 24 months, the mean creatinine within 7–365
days provided best correlation [15]. In contrast, we found that
the novel combination of NHS England algorithm criteria was
more sensitive than any single deﬁnition using a clinically rele-
vant reference standard.
The three combined criteria of the NHS England algorithm
were also more sensitive for ICD-10 AKI than the two criteria
used in a recent randomized controlled trial that did not report
beneﬁt from alerts [12]. Wilson and colleagues restricted their
AKI criteria to changes within the previous week (criteria 2 and 3),
but in our study we found this reduced sensitivity for ICD-10
AKI to 74.2%. In addition, at the time of ﬁrst alert, we found
that 41% of NHS England algorithm patients had a reference
creatinine more than a week ago. These are patients who
would either have received no alert or a delayed alert in the
trial. A total of 67.3% of AKI occurs at the point of hospital ad-
mission or within two days of admission [29], but in the trial of
Wilson and colleagues most alerts occurredmore than two days
after admission. Delays in alerting may therefore have reduced
the potential for improving outcomes. This highlights the need
to assess the timeliness of an alert algorithm as well as its
accuracy.
As the NHS England algorithm is intended to improve AKI
recognition, we focussed on assessing its sensitivity, using
ICD-10 clinical coding (N17) as a subset of clinically conﬁrmed
AKI patients. N17 had a high speciﬁcity for the KDIGO AKI
deﬁnition in a single centre in 2005 [23] and for this reason
we also restricted to N17 codes (‘acute renal failure’), and not
N19 (‘unspeciﬁed kidney failure’). ICD-10 AKI is therefore a
useful reference test for testing sensitivity, but as it is only a sub-
set of AKI we could not use it to assess speciﬁcity or false-
positive rates and this is a limitation of our study. Nevertheless,
the presence of false-positives is implied by the large variation
in patients alerted with subsequent modiﬁcations to the algo-
rithm. Further testing of speciﬁcity and positive predictive
values would be appropriate, in addition to providing evidence
of clinical beneﬁt.
A further limitation is the time period (2003) as AKI has re-
cently gained greater attention and coding has increased [23].
Nevertheless, while more patients are recognized and coded,
the speciﬁcity of ICD-10 AKI remained unchanged between
2005 and 2010 [23]. As our study relied on a correct diagnosis
in ICD-10 rather than high proportion of true AKI patients
being coded, our use of codes in this time period is justiﬁed
and our ﬁndings applicable.
We deviated from the NHS England algorithm in two re-
spects. As sample time data were incomplete, we used ‘2 days’
rather than ‘48 h’ for criterion 3. This could overestimate AKI,
so in sensitivity analysis we reduced the window to 1 day, which
would underestimate AKI.With this change, 52 patients moved
from biochemical AKI to no AKI on NHS England criteria,
none with ICD-10 codes. In addition, we included only the
highest creatinine on each day. This prevented spurious sam-
ples causing false positives, but could underestimate AKI. In
sensitivity analysis all results were included and 127 patients
without biochemical AKI now had AKI, including four with
ICD-10 codes. These changes do not greatly affect our ﬁndings,
but do reﬂect some of the considerations required for the prag-
matic application of an automated algorithm without manual
checking.
Notably, oliguria is not in theNHS England algorithm, but is
part of the KDIGOAKI criteria andmay be the ﬁrst sign of AKI
[6]. Some patients with ICD-10 AKI were missed due to inad-
equate baseline data and could be found by extending the look-
back, but a lack of oliguria data may be another explanation.
Finally, in this study, we identiﬁed AKI patients rather than
AKI events. This means that we did not capture repeat admis-
sions, or changes in clinical care. While this has advantages in
not over-representing AKI recurrence or misdiagnosing non-
recovery as a repeat event, changes in clinical care such as hos-
pital admission and transfers to critical-care setting should be
investigated in future studies.
We noted three challenging groups of patients in this study.
First, if a patient presents with an abnormal creatinine but no
previous tests, AKI may only become apparent if the creatinine
subsequently falls. The NHS England AKI algorithm includes a
ﬂag for such tests (13 064 blood tests in our cohort), but this re-
quires good clinical judgment. Second, a patient may develop
AKI but still have a normal eGFR and be overlooked. This
was rare (AKI occurred in 0.9% of patients with normal
tests), but these patients are still identiﬁed by the algorithm
and should not be dismissed on absolute values. Third, 19.3%
of AKI patients were out of hospital at ﬁrst detection. Future
studies should develop an evidence base on how an alert algo-
rithm would affect the community.
Our key ﬁnding in this study was the encouraging perform-
ance of the NHS England algorithm (92.1% sensitive in detect-
ing clinically ICD-10 AKI), but coded cases were still missed.
There were also large variations in patients detected and missed
with algorithm modiﬁcations. The timeliness of an alert may
also be inﬂuenced by different deﬁnitions of AKI. The AKI def-
inition is important not only in automated AKI detection in
clinical practice where there is a trade-off between sensitivity
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and overburdening clinicians with ‘alert fatigue’ [13, 14], but
also in clinical research where inconsistent deﬁnitions will re-
sult in selection biases. A distinction should be made between
automated detection to assist early detection, and automated
detection for diagnosis and clinical research. In research involv-
ing AKI patients, we recommend reporting the patient selection
method so that limitations are transparent. In clinical practice,
we show that automated alerts may be helpful, but the diagnosis
of AKI depends on the clinician who must recognize cases of
misclassiﬁed CKD or AKI without a previous baseline. Evi-
dence of survival beneﬁt is also still lacking. It is necessary to
understand the best way to deliver alerts in a timely fashion
so that they target the right patients and circumstances where
most beneﬁt can be provided.
In this study, the combined NHS England AKI algorithm
criteria performed well as a diagnostic adjunct, identifying pa-
tients with an ICD-10 AKI code better than any individual AKI
deﬁnition or previously studied deﬁnition. A trade-off existed
between diagnostic sensitivity and ‘alert burden’. Clinicians
should be mindful of this when interpreting an alert for an in-
dividual patient.
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